Home › OncoMed Pharmaceuticals CEO Testifies on Behalf of BIO at Congressional Hearing on FDA Drug ...
 

Keywords :   


OncoMed Pharmaceuticals CEO Testifies on Behalf of BIO at Congressional Hearing on FDA Drug ...

2013-12-12 06:00:00| Industrial Newsroom - All News for Today

House Committee on Oversight & Government Reform, Subcommittee on Energy Policy, Health Care & Entitlements held a hearing entitled, "FDA Check-Up: Drug Development and Manufacturing Challenges." Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Chairman of BIO’s Emerging Companies Section Governing Board, presented testimony emphasizing the positive indicators that demonstrate the biopharma industry is rebounding, but significant financial and regulatory challenges ...This story is related to the following:Green & CleanSearch for suppliers of:

Tags: on drug behalf bio

Category:Industrial Goods and Services

Latest from this category

All news
17.05Next MANAchat Series Scheduled for the Week of June 10
15.05Relationship Reviews Strengthening the Partnership Between Manufacturer and Rep
14.05Consolidated Financial Statements for the twelve-month period ended March 31, 2024
14.05Actions to Implement Management that is Conscious of Cost of Capital and Stock Price
Industrial Goods and Services »
19.05Fujitsu sacked boss at height of Horizon scandal
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05M&S website and app hit by technical issue
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
More »